NuCana® is a rapidly growing, Phase III clinical stage biopharmaceutical company developing an expansive portfolio of new medicines to treat cancer. With its new generation of anti-cancer agents (nucleotide analogues), NuCana is setting advanced benchmarks for innovative treatments. NuCana is transforming anti-cancer agents (nucleoside analogues) into better and safer medicines that overcome key tumour resistance mechanisms.
Our state-of-the-art ProTide technology ensures that significantly more active agent is being generated within the cancer cells. Acelarin (NUC-1031) is NuCana’s first ProTide to enter the clinic and has achieved exceptional levels of disease control in a comprehensive study of patients with advanced, rapidly progressing solid tumours.
NuCana has a wide ProTide technology pipeline with several new families in late stage non clinical development. Two additional ProTides have entered the IND enabling stage of development and are scheduled to reach the clinic in the next 3 to 12 months.
A Phase III study of Acelarin as first-line treatment against pancreatic cancer was initiated in Q1 2016. Acelarin has entered into a combination study with carboplatin to assess the safety and clinical activity of the regimen in patients with ovarian cancers. In addition, a combination study with cisplatin for patients with biliary cancers was initiated in Q1 2016.